Viable Parenchymal Neurocysticercosis (>2 Cysts): What to Do When Initial Antiparasitic Combination Fails
This protocol applies when a patient with viable parenchymal neurocysticercosis and more than two viable cysts has completed a full first-line antiparasitic course but has not achieved the expected radiologic response.
Viable parenchymal neurocysticercosis with more than 2 viable parenchymal cysticerci and no elevated intracranial pressure. Antiparasitic therapy is indicated in this population; combined antiparasitic regimens are preferred over monotherapy for patients with this cyst burden.
The previous course — albendazole combined with praziquantel, with adjunctive corticosteroid therapy — did not achieve the key therapeutic goal: radiologic resolution of the parenchymal cystic component on MRI by 6 months. Persistent cystic lesions at that interval trigger escalation to this retreatment protocol.
References
- In the absence of elevated intracranial pressure, we recommend use of antiparasitic drugs in all patients with VPN (strong, moderate).
- We recommend albendazole (15 mg/kg/day) combined with praziquantel (50 mg/kg/day) for 10–14 days rather than albendazole monotherapy for patients with >2 viable parenchymal cysticerci (strong, moderate).
- We suggest retreatment with antiparasitic therapy for parenchymal cystic lesions persisting for 6 months after the end of the initial course of therapy (weak, low).